menu
    • menu

    Company profile for OliX Pharmaceutical

    NEW Drugs in Dev: 7
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    OliX is a clinical stage biotechnology company, based on our own proprietary RNA interference (RNAi) technology regulating the expression of disease-causing genes. Since the discovery of a RNAi technology, it has been widely recognized as the third drug development platform after small molecule and protein(antibody) drugs, which is now changing the paradigm of a therapeutic development.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    OliX Pharmaceuticalkorearepublicofnew Flag
    Country
    Country
    South Korea
    Address
    Address
    17 Daehak 4-ro, Yeongtong-gu, #1014 Gwanggyo Ace Tower, Suwon-si, Gyeonggi-do ...
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    http://www.olixpharma.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/olix/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Lilly inks OliX deals to expand in MASH
    Lilly inks OliX deals to expand in MASH

    11 Feb 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20250210958713/en/OliX-and-Lilly-Enter-Global-Licensing-Agreement-for-MASH-and-Other-Cardiometabolic-Indications

    BUSINESSWIRE
    11 Feb 2025
    Share Share
    OliX Pharma Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH
    OliX Pharma Receives HREC Approval to Initiate Phase 1 Clinical Trial of NASH

    22 Dec 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20231222734122/en

    BUSINESSWIRE
    22 Dec 2023
    Share Share
    OliX Administers First Patient in Phase 1 Clinical Study of OLX72021
    OliX Administers First Patient in Phase 1 Clinical Study of OLX72021

    13 Jun 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230613956249/en

    BUSINESSWIRE
    13 Jun 2023
    Share Share
    OliX Presents Data Showing Weight Loss from anti-NASH siRNA and Semaglutide
    OliX Presents Data Showing Weight Loss from anti-NASH siRNA and Semaglutide

    11 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230511005361/en

    BUSINESSWIRE
    11 May 2023
    Share Share
    OliX Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy
    OliX Inks MOU with DynamiCure Biotechnology to Develop ADC Immunotherapy

    10 May 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230510005383/en

    BUSINESSWIRE
    10 May 2023
    Share Share
    OliX Announces Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar
    OliX Announces Results from a Phase 2a Trial of OLX10010 for Hypertrophic Scar

    28 Apr 2023

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20230428005123/en

    BUSINESSWIRE
    28 Apr 2023
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search